Cross-Sector entity
Wall Street Zen is the most frequent co-covered peer, appearing in 13 of the 20 tracked stories. That works out to roughly 15.6 stories per week across a 9-day span. The busiest single day carried 6. markets accounts for 7 of the 20 tracked stories, while 6 other categories carry the remainder.
90 verified stories tracked
Last mentioned: 14h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Wall Street Zen is the most frequent co-covered peer, appearing in 13 of the 20 tracked stories. That works out to roughly 15.6 stories per week across a 9-day span. The busiest single day carried 6. markets accounts for 7 of the 20 tracked stories, while 6 other categories carry the remainder. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment. This profile follows 20 Cross-Sector stories mentioning Weiss Ratings across the period from August 16, 2026 to August 24, 2026.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Weiss Ratings. Shared-story counts are live from our verified record — not editorial picks.
Dividend payment
The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Ex-dividend date
Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
AECOM Reports Q2 Loss and Issues FY2026 Guidance
AECOM posted a Q2 loss of $0.50 per share on $3.59B revenue and guided FY2026 EPS to $3.95-$4.15, far below consensus.
Amentum Updates FY2026 Guidance
Amentum guided FY2026 EPS to $2.40-$2.50 and revenue to $13.8B-$14.0B, missing revenue consensus.
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
A Q2 13F filing shows Northwestern Mutual Wealth Management initiated a $106.97M RTX position and an $18.25M Cummins stake. Analysts are raising price targets on both names, reinforcing institutional conviction in industrial cyclicals.
Source: Watch List News · Bbns
Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Keysight Technologies beat Q3 estimates and raised full-year EPS guidance to $11.46 on $7.1 billion revenue, yet shares sold off 5.5% on the news. The reaction highlights valuation concerns despite a forward P/E of about 30.
Source: MarketBeat · dailypolitical.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Source: tickerreport.com · themarketsdaily.com
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Silexion beat consensus by $16.03 with a ($5.17) EPS, yet shares fell to $0.42. With volume at 2x average, a 52-week high of $80, and Hold consensus, the microcap has shed nearly all value.
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
Institutional 13F data shows new accumulation in Chubb as small advisory firms added positions from Q4 2025 through Q2 2026. Analyst targets range from $301 to $386, while insider sales and 83.81% institutional ownership frame a mixed but liquid market for CB.
Source: Ticker Report · Daily Political
